The abstract is read at the publisher; the summary is JClub's.
Saroglitazar 4 mg for 24 weeks significantly reduced hepatic fat in women with PCOS and MASLD, with MRI proton density fat fraction dropping by -14.81±5.52% versus 1.96±5.75% on placebo.
- Why it matters: Women with PCOS commonly have MASLD but are underrepresented in therapeutic trials, leaving limited evidence on safe, effective liver-directed treatments for this group.
- What they did: In a multicenter, randomized, double-blind phase 2A trial, 60 women aged 18–45 years with PCOS and MASLD received saroglitazar 4 mg or placebo for 24 weeks; hepatic fat was measured by MRI proton density fat fraction.
- The result: Saroglitazar also increased the proportion achieving ≥30% fat reduction (36.0% vs 8.7%) and significantly lowered aminotransferases, lipid parameters, and FibroScan AST score, with adverse events comparable and no serious events.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.